Amylyx Pharmaceuticals, Inc. (AMLX)

Amylyx Pharmaceuticals Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Assets

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Cash & Equivalents	240.1	226.65	77.39	170.2	62.53	50.19
Short-Term Investments	528.04	90.33	99.11	201.16	284.42	45.93
Cash & Short-Term Investments	768.13	316.98	176.5	371.36	346.95	96.12
Cash Growth	123.30%	79.59%	-52.47%	7.04%	260.96%	646.43%
Accounts Receivable	-	0.09	0.45	40.05	15.31	-
Other Receivables	2.9	0.1	0.1	0.5	0.5	-
Receivables	2.9	0.19	0.55	40.55	15.81	-
Inventory	-	-	-	38.32	9.77	-
Prepaid Expenses	7.83	6.5	12.38	14.43	9.61	5.39
Other Current Assets	-	-	-	-	-	3.44
Total Current Assets	778.86	323.67	189.43	464.67	382.13	104.95
Property, Plant & Equipment	4.44	5.49	2.73	6.41	8.14	0.47
Other Long-Term Assets	3.5	3.48	1.47	46.38	1.19	0.19
Total Assets	786.8	332.65	193.63	517.45	391.45	105.61

Liabilities

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Accounts Payable	4.8	3.52	2.94	22.06	6.26	4.37
Accrued Expenses	23.31	17.91	23.95	57.72	38.31	13.02
Current Portion of Leases	0.93	1.26	1.52	2.26	2.04	-
Total Current Liabilities	29.05	22.69	28.41	82.04	46.61	17.4
Long-Term Leases	4.01	4.7	0.46	1.98	4.24	-
Other Long-Term Liabilities	-	-	-	-	-	0.04
Total Liabilities	33.06	27.39	28.87	84.02	50.85	17.43

Shareholders' Equity

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Common Stock	0.01	0.01	0.01	0.01	0.01	0
Additional Paid-In Capital	1,636	1,056	771.54	738.18	694.91	4.67
Retained Earnings	-881.62	-751.43	-606.69	-304.95	-354.22	-155.85
Comprehensive Income & Other	-0.18	0.4	-0.09	0.2	-0.09	0.01
Total Common Equity	753.74	305.26	164.77	433.43	340.61	-151.17
Shareholders' Equity	753.74	305.26	164.77	433.43	340.61	88.18
Total Liabilities & Equity	786.8	332.65	193.63	517.45	391.45	105.61

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Total Debt	4.94	5.96	1.98	4.24	6.28	-
Net Cash (Debt)	763.19	311.02	174.52	367.13	340.67	96.12
Net Cash Growth	125.76%	78.22%	-52.46%	7.77%	254.43%	739.31%
Net Cash Per Share	6.77	3.29	2.56	5.25	5.82	14.59
Filing Date Shares Outstanding	128.56	110.54	88.6	67.78	66.72	57.86
Total Common Shares Outstanding	128.54	109.88	68.63	66.51	66.51	7.02
Working Capital	749.81	300.98	161.03	382.62	335.52	87.56
Book Value Per Share	5.86	2.78	2.40	6.52	5.12	-21.53
Tangible Book Value	753.74	305.26	164.77	433.43	340.61	-151.17
Tangible Book Value Per Share	5.86	2.78	2.40	6.52	5.12	-21.53
Machinery	-	1.69	1.92	3.55	2.17	0.34
Construction In Progress	-	0.02	0.22	0.59	0.8	0.14
Leasehold Improvements	-	0.15	0.18	0.18	0.18	0.05

SEC Filings: 10-K · 10-Q

Data Source: S&P Global Market Intelligence Last updated: Nov 5, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Nov 11, 2026

Data Sources Report a data error